Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04117789
Other study ID # 2019-03235
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 14, 2019
Est. completion date October 21, 2020

Study information

Verified date October 2020
Source Karolinska Institutet
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Prior to a properly powered randomized controlled study, evaluating efficacy and cost-effectiveness of ICBT, we will conduct a pilot study to investigate if the trial design is feasible, if therapist-guided and self-guided internet-delivered cognitive behavioral therapy (ICBT) is acceptable for adolescents with depression and to provide preliminary clinical efficacy data.


Description:

A single-blind parallel-group pilot randomised controlled feasibility trial with the overall aim to develop two internet-delivered cognitive behaviour therapy interventions, therapist-guided and self-guided, for adolescents with mild to moderate Major Depressive Disorder (MDD) and their primary caregivers. Patients can be either referred or self-referred. All potential participants are initially screened via telephone. This is followed by a face-to-face inclusion assessment. Participants who are eligible and have consented will be randomized into one of three trial arms; therapist-guided ICBT, self-guided ICBT or TAU. In the experimental arms, participants, e.g. the adolescent and at least one caregiver, either receive 10 weeks of therapist-guided or self-guided internet-delivered behavioural activation (BA). In the control arm, participants receive treatment as usual within the Child and Adolescent Mental Health Services (CAMHS) or primary care clinics. The primary endpoint will be at 3-month follow-up. The primary objective is to evaluate the feasibility of the study design and trial procedures, including recruitment, withdrawal, drop out and attrition rates. The secondary objective is to (a) evaluate the acceptability of the ICBT interventions in regard to treatment satisfaction, credibility, reported adverse events, and program use, (b) to provide preliminary clinical efficacy data, and (c) to gather qualitative information on the experience of undergoing ICBT for depression from the perspective of adolescent patients, their caregivers and potential areas for improvement of future ICBT interventions.


Recruitment information / eligibility

Status Completed
Enrollment 32
Est. completion date October 21, 2020
Est. primary completion date October 15, 2020
Accepts healthy volunteers No
Gender All
Age group 13 Years to 17 Years
Eligibility Inclusion Criteria: - Primary diagnosis of mild to moderate MDD according to the Diagnostic and Statistical Manual of Mental Disorders, 5th ed. - Willing to be randomized to either of the three treatment arms. - Basic proficiency in Swedish, both adolescent and participating care-giver - Regular access to a desktop or laptop computer connected to the internet, as well as a mobile phone to receive sms (one of each is enough per family). - Stable medication with antidepressants, central stimulants and neuroleptics at least 6 weeks prior to inclusion. - A minimum of one caregiver that is able to co-participate in the treatment. Exclusion Criteria: - Immediate risk to self or others, requiring urgent medical attention, such as suicidality, or repeated self-injurious behaviour. - Other severe psychiatric disorders requiring other actions at first hand (e.g. diagnosis of organic brain disorder, intellectual disability, psychosis, bipolar disorder, eating disorder, or alcohol/substance dependence; - Current social problems requiring other actions at first hand (e.g. bullying in school, abuse and/or neglect in the family; high and prolonged absence from school). - Previous CBT for MDD within the last 12 months prior to assessment, for a minimum of 3 sessions other than psychoeducation with a qualified therapist within the 12 months prior to assessment. - Current use of benzodiazepines. - An ongoing psychological treatment for any other psychiatric disorder.

Study Design


Intervention

Behavioral:
Therapist-guided internet-delivered cognitive behavior therapy for depression in adolescents
Participants will be assigned to a 10 weeks internet-delivered cognitive behavior therapy program with therapist support via an internet platform.
Self-guided internet-delivered cognitive behavior therapy for depression in adolescents
Participants will be assigned to a 10 weeks internet-delivered cognitive behavior therapy program without therapist support via an internet platform.
Other:
Treatment as usual
Participants randomized to TAU, will be referred to the local CAMH's or primary care unit for children and youths and will be free to receive any treatment, either psychosocial, medical or the combination of both.

Locations

Country Name City State
Sweden Child and Adolescent Psychiatry Research Center Stockholm

Sponsors (2)

Lead Sponsor Collaborator
Karolinska Institutet Stockholm County Council, Sweden

Country where clinical trial is conducted

Sweden, 

Outcome

Type Measure Description Time frame Safety issue
Other Behavioral activation of Depression Scale - short form (BADS-S) The BADS-S is designed to track changes in proposed mediators of behavioral activation, e.g. activation and avoidance. Total range is from 0-54 with higher values indicating higher degree of activation and lower degree of avoidance.
Changes during treatment in proposed mediators of behavioral activation on the BADS-S will be reported for the ICBT interventions.
weekly during treatment (week 1 to week 10)
Other Trimbos Questionnaire for Costs associated with Psychiatric Illness (TiC-P) The TiC-P assess healthcare and societal resource use, including for example items on healthcare resource use, medications, school absenteeism, and parental productivity loss. In the present study no health economic evaluations will be conducted. Rather this instrument is included to gain feasibility data in preparation of a planned larger randomized controlled study. Therefore, no data on TiC-P will be reported in this trial. week 0, week 10, at 3 months follow-up
Primary Children's Depression Rating Scale - Revised (CDRS-R) CDRS-R is a semi-structured clinician interview, assessing level of depressive symptomatology. Total range is 17-113, with higher values representing a worse outcome. Change from baseline in depressive symptom severity on the CDRS-R at end of treatment, and at 3-months follow-up will be reported. Primary endpoint is 3 months follow-up. week 0, week 10, at 3 months follow-up
Secondary Treatment credibility and expectancy scale - adolescent and parent version This scale consists of four qualitative questions about treatment credibility, asking how well the treatment suits adolescents with depression, how much they believe this treatment will help him/her, if and to what extent they would recommend this treatment to a friend with depression and how much improvement they expect from the treatment. Total range is 4-20, with higher values representing higher credibility. Mean in total treatment credibility score on the "Treatment credibility scale" for each treatment group at week 3 will be reported. week 3
Secondary The Client Satisfaction Questionnaire-8 (CSQ-8) - adolescent and parent version The CSQ-8 is an 8-item self-rated 4-point scale, measuring different aspects of satisfaction with treatment, e.g. perception of quality of treatment, if the treatment adequately addressed their needs and overall satisfaction. Total range is 8 to 32, with higher values indicating higher satisfaction. Mean in total satisfaction scores on the CSQ-8 for each treatment group at end of treatment and at follow-up will be reported. week 10, at 3 months follow-up
Secondary Need for further treatment - adolescent and parent version Investigate whether the participant considers her/himself in need of further treatment for her/his depression. week 10, at 3 months follow-up
Secondary Negative Effects Questionnaire (NEQ-20) - adolescent and parent version NEQ-20 investigate participants' negative effects of psychological treatments. Total range is 0-80, with higher values representing a worse outcome.
Descriptive data in negative effects of treatments on the NEQ-20 will be reported for participants randomized to either of the ICBT interventions at mid treatment, after end of treatment and at 3 months follow-up.
week 5, week 10, at 3 months-follow up
Secondary Treatment completion Adherence in terms of numbers of completed chapters for patients and their parents respectively in the ICBT interventions will be reported after 10 weeks. This data will be collected from the IT platform that delivers the ICBT interventions. week 10
Secondary Therapist time Total therapist time per patient an week will be reported for the ICBT interventions at the end of the pilot study. This data will be collected from the IT platform that delivers the ICBT interventions. week 1 to week 10
Secondary Clinical Global Impression Scale - Severity (CGI-S) CGI-S is developed to assess how mentally ill a specific patient compared to a particular patient population (e.g. with major depressive disorder) at a certain time.
It consists of a single item rated on a seven-point scale ranging from 1="no symptoms" to 7="extreme symptoms". Change from baseline in global severity of depressive symptoms on the CGI-S at end of treatment, and at 3 months follow-up will be reported.
week 0, week 10, at 3 months follow-up
Secondary Clinical Global Impression - Improvement (CGI-I) CGI-I is developed to assess improvement of psychiatric symptoms for a specific patient compared to baseline. It consists of a single item rated on a seven-point scale ranging from 1="very much improved" to 7="very much worse". Change from baseline in global improvement of depressive symptoms to end of treatment and at 3 months follow-up on the CGI-I will be reported. week 10, at 3 months follow-up
Secondary Children's global assessment scale (CGAS) The CGAS is a single item 1-100 scale that integrates psychological, social, and academic functioning in children as a measure of psychiatric disturbance. Higher values represent a worse outcome. Change from baseline in global functioning CGAS to end of treatment and at 3 months follow-up will be reported. week 0, week 10, at 3 months follow-up
Secondary Short Mood and Feeling Questionnaire (SMFQ) - adolescent and parent version The SMFQ is a 13-item self-reported measure of depressive symptoms. Total range is 0-26, with higher values representing a worse outcome. Change from baseline in adolescent- and parent-rated depressive symptoms on the SMFQ to week 10 and at 3 months follow-up, and weekly during treatment will be reported.
Additionally, for this trial, we have also added a 14th item, aimed to assess suicide risk. This item is not included in the total score.
week 0, weekly from week 1 to week 10, at 3 months follow-up
Secondary The Revised Children's Anxiety and Depression Scale, short (RCADS-S) -adolescent and parent version The RCADS-S, a shortened version of the Spence Child Anxiety Scale, is a child and parent self-report measure of anxiety- and depression-related psychopathology. Only the anxiety subscales are administered in this study, since depressive symptoms are measured thoroughly by other measures. Total range is 0-45, with higher values representing a worse outcome. Change from baseline in adolescent- and parent-rated depressive symptoms on the RCADS-S to end of treatment and at 3 months follow-up will be reported. week 0, week 10, 3 months follow-up
Secondary Affective Reactivity Index (ARI) - adolescent and parent version ARI is a parent- and self-rated measure of irritability and impairment due to irritability. Total range is 0-12, with higher values representing a worse outcome. Change from baseline in adolescent- and parent-rated irritability and impairment due to irritability on the ARI to end of treatment, and at 3-months follow-up will be reported. week 0, week 10, 3 months follow-up
Secondary Insomnia Severity Index (ISI) ISI, a brief screening measure of insomnia, a seven-item scale ranging from 0 to 28 points, with higher values representing a worse outcome. Change from baseline in sleep problems on ISI to end of treatment at 3 months follow-up will be reported. week 0, week 10, at 3 months follow-up
Secondary Work and Social Adjustment Scale, youth version (WSAS-Y) - adolescent and parent version WSAS-Y is a parent- and adolescent-rated scale of impaired functioning in school, everyday life, friends and social life, recreation and hobbies and family and close relationships. The scale generates a global score ranging from 0 to 40, with higher scores indicating greater impairment. Change from baseline in adolescent- and parent rated impairment and functioning on the WSAS-Y will be reported at the end of treatment, and at 3 months follow-up. week 0, week 10, 3 months follow-up
Secondary Working Alliance Inventory, Short (WAI-S) - adolescent and parent version The WAI-S is scale measuring the participants perceived working alliance with their therapist. Total range 12-84, with higher scores indicating a better working alliance. Descriptive data on participants' perceived working alliance with their therapist, or with the program for participants in the self-guided ICBT, on the WAI-S will be reported at end of treatment and at 3-months follow up. week 10, 3 months follow-up
Secondary Kidscreen-10 Index - adolescent and parent version Kidscreen-10 assess the adolescents' general health-related quality of life. Total range from 10-50, with higher values indicating better health-related quality of life. Change from baseline in general health-related quality of life on the Kidscreen-10 will be reported at the end of treatment and at 3 months follow-up. week 0, week 10, at 3 months follow-up
See also
  Status Clinical Trial Phase
Recruiting NCT05537558 - Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
Terminated NCT02192099 - Open Label Extension for GLYX13-C-202, NCT01684163 Phase 2
Completed NCT03142919 - Lipopolysaccharide (LPS) Challenge in Depression Phase 2
Recruiting NCT05547035 - Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders N/A
Terminated NCT02940769 - Neurobiological Effects of Light on MDD N/A
Recruiting NCT05892744 - Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression Phase 4
Recruiting NCT05537584 - SMART Trial to Predict Anhedonia Response to Antidepressant Treatment Phase 4
Active, not recruiting NCT05061706 - Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder Phase 3
Completed NCT04479852 - A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder Phase 2
Recruiting NCT04032301 - Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans Phase 1
Recruiting NCT05527951 - Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study N/A
Completed NCT03511599 - Cycloserine rTMS Plasticity Augmentation in Depression Phase 1
Recruiting NCT04392947 - Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation N/A
Recruiting NCT05895747 - 5-HTP and Creatine for Depression R33 Phase Phase 2
Recruiting NCT05273996 - Predictors of Cognitive Outcomes in Geriatric Depression Phase 4
Recruiting NCT05813093 - Interleaved TMS-fMRI in Ultra-treatment Resistant Depression N/A
Recruiting NCT05135897 - The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
Enrolling by invitation NCT04509102 - Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder Early Phase 1
Recruiting NCT06026917 - Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET) Phase 4
Recruiting NCT06145594 - EMA-Guided Maintenance TMS for Depression N/A